Effect of time-of-day nivolumab and stereotactic body radiotherapy in metastatic head and neck squamous cell carcinoma: A secondary analysis of a prospective randomized trial.
Head Neck
; 46(9): 2292-2300, 2024 09.
Article
en En
| MEDLINE
| ID: mdl-38794815
ABSTRACT
BACKGROUND:
Prior work documented circadian rhythm impacts on efficacy and toxicity of cancer therapies.METHODS:
Secondary analysis of prospective, phase II trial of metastatic HNSCC randomized to nivolumab+/-SBRT. Used cutoffs of 1100 and 1630. Timing classified by first infusion or majority of SBRT (e.g., PM SBRT defined by two or three fractions after 1630).RESULTS:
Of 62 patients, there was no significant difference in median PFS between AM nivolumab (n = 7, 175 days), PM nivolumab (n = 21, 58 days), or Mid-Day nivolumab (n = 34, 67 days; p = 0.8). There was no significant difference in median PFS with AM SBRT (n = 4, 78 days), PM SBRT (n = 13, 111 days), or Mid-Day SBRT (n = 15, 63 days; p = 0.8). There was no significant difference in Grade 3-4 toxicity or ORR. Sensitivity analyses with other timepoints were negative.CONCLUSIONS:
Further work may elucidate circadian impacts on select patients, tumors, and therapies; however, we found no significant effect in this study.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Radiocirugia
/
Carcinoma de Células Escamosas de Cabeza y Cuello
/
Nivolumab
/
Neoplasias de Cabeza y Cuello
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Head Neck
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos